Apnimed, Inc. (APMD) Stock Price & Analysis
Apnimed, Inc. (APMD) is trading at USD 17.4, down 9.13% today, as of October 29, 2026 at 18:51 UTC (US market open; quotes may be delayed), according to Nexqual market data.
APMD last closed at USD 19.15; today's session has ranged USD 17–19.19 on volume of 603,215 shares. Market capitalization is $724.42M, with a 52-week range of USD 16.12–35.29 (NMS). Source: Nexqual, retrieved October 29, 2026 at 18:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/APMD.md
Key facts (APMD)
- Valuation: P/E 7.6x, net cash $133M.
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $5.2M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 50.33 (range 41–60).
- Total return with dividends: 1Y -30.4% vs S&P 500 +12.8%; 5Y -30.4% vs S&P 500 +78.6%.
- Next earnings: 2026-11-11, EPS estimate USD -0.6, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (APMD)
P/E 7.6x · Earnings yield 13.19% · Net cash $133M · EV $592M
Insider purchases (SEC Form 4, open-market, last ~7 months) (APMD)
2 purchases, $5.2M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-03 | Morningside Venture Investments Ltd | 312,500 | $5.0M | 16 | Too little history (no open-market trades in 2023–2025) | |
| 2026-08-03 | Sekhri Paul J | Director | 12,500 | $200K | 16 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (APMD)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 50.33 (low 41, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | LifeSci Capital | Initiated | Outperform | $50 |
| 2026-08-25 | Cantor Fitzgerald | Initiated | Overweight | $60 |
| 2026-08-25 | Evercore ISI Group | Initiated | Outperform | |
| 2026-08-25 | B of A Securities | Initiated | Buy | $41 |
Total return (dividends reinvested) (APMD)
| 1Y (from 2026-07-31) | 5Y (from 2026-07-27) | |
|---|---|---|
| Total return | -30.4% | -30.4% |
| S&P 500 (SPY) | +12.8% | +78.6% |
| Per year | — | — |
| Volatility (annualized) | 93.0% | 89.4% |
| Max drawdown | -49.0% (Aug 2026→Oct 2026) | -45.2% (Aug 2026→Oct 2026) |
APMD earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.42 | −$0.34 | Miss −23.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
APMD recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 8, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Sep 8, 2026 | 8-K | Quarterly results |
| Aug 7, 2026 | Schedule 13G | Ameriprise Financial, Inc., Columbia Management Investment Advisers, LLC: 18.9% of shares, passive 5%+ holder |
| Aug 6, 2026 | Schedule 13G | Tao Capital Management LP, Tao Invest VI LLC: 5.2% of shares, passive 5%+ holder |
| Aug 3, 2026 | 8-K | Bylaws or fiscal-year change |
| Jul 27, 2026 | S-1/A | Registration of new shares |
| Jul 10, 2026 | S-1 | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
APMD company outlook (results filed Sep 8, 2026)
- “The net decrease was primarily driven by $7.6 million lower clinical trial expense related to AD109 (proposed proprietary name Oxnimbi) as LunAIRo and SynAIRgy trials were completed in 2025, and $0.1 million decrease in other projects expense.”
Quoted word-for-word from the SEC 8-K results press release.
APMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.60 | $0.00 | −$0.60 | $0 | 2 |
| Next quarter (ends Dec 2026) | $-0.72 | $0.00 | −$0.72 | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-0.06 | $0.00 | −$0.06 | $90.8M | 1 |
| Next fiscal year (ends Dec 2027) | $-3.98 | $0.00 | −$3.98 | $22.4M | 4 |
Key Statistics (as of October 29, 2026 at 18:51 UTC)
| Price | USD 17.4 |
|---|---|
| Change | ▼ 9.13% (down) |
| Previous Close | USD 19.15 |
| Open | USD 19.15 |
| Day Range | USD 17 – 19.19 |
| 52-Week Range | USD 16.12 – 35.29 |
| Volume | 603,215 shares |
| Market Cap | $724.42M |
| Exchange | NMS |
Technical Analysis (APMD)
Nexqual's technical model rates APMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 64 daily candles, as of October 29, 2026 at 18:51 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.96 (neutral) |
| vs SMA50 | Below (USD 23.18) |
| MACD | -1.27 (negative) |
Analyst Ratings (APMD)
Wall Street analysts rate APMD "Buy" based on 4 analysts, with a mean price target of USD 50.33 (range USD 41–60), per Nexqual as of October 29, 2026 at 18:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 50.33 |
| High Target | USD 60 |
| Low Target | USD 41 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (APMD)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.6 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.42 vs est -0.34 ▼ miss |
Source: Nexqual, October 29, 2026 at 18:51 UTC.
Financials & Fundamentals (APMD)
| Total Revenue | $115.12M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -29.40% |
| Gross Margin | +93.90% |
| Operating Margin | -96.89% |
| Profit Margin | +142.10% |
| Debt / Equity | 1.3 |
| Current Ratio | 5.19 |
| Total Cash | $172.80M |
| Total Debt | $90.39M |
Source: Nexqual, October 29, 2026 at 18:51 UTC.
Financial Health Score (APMD)
Nexqual rates Apnimed, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 18:51 UTC.
| Growth | Critical — Revenue -29% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $173M cash and investments vs $40M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$70M (TTM) |
| Efficiency | Strong — ROE not meaningful (negative equity); ROA 48.9% (last 4 quarters, SEC) |
Ownership (APMD)
| Insider Ownership | +35.61% |
|---|---|
| Institutional Ownership | +24.98% |
| Shares Outstanding | 41.63M |
| Float | 20.46M |
Source: Nexqual, October 29, 2026 at 18:51 UTC.
Leadership (APMD)
Apnimed, Inc. is led by Kevin Robert Lind, CEO & Director, per Nexqual as of October 29, 2026 at 18:51 UTC.
| CEO & Director | Kevin Robert Lind |
|---|---|
| President & COO | Dennis Patrick Molnar |
| Co-Founder & Chief Scientific Officer | Luigi Taranto Montemurro |
| Chief Financial Officer | Michael B. Kelly |
| Senior Vice President of Human Resources | Jennifer Patterson |
Major Backers & Investors (APMD)
Notable institutional backers of Apnimed, Inc. include AB CAP FUND, INC.-AB Small Cap Growth Portfolio, Fidelity, according to Nexqual as of October 29, 2026 at 18:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 0.72% |
| Fidelity | 0.69% |
Source: Nexqual, October 29, 2026 at 18:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.67 | ▼ 0.32% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 311.23 | ▼ 2.37% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 9.85 | ▼ 33.49% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.37 | ▼ 1.18% |
| AXSM | Axsome Therapeutics, Inc. | USD 140.97 | ▼ 1.77% |
| ABVX | Abivax SA | USD 88.8 | ▼ 1.16% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 18:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt